This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

New Indication for Thoracotomy

Carl A. Bertelsen, MD; David H. Kern, PhD; Larry R. Kaiser, MD; Barry D. Mann, MD; E. Carmack Holmes, MD; Donald L. Morton, MD

Arch Surg. 1983;118(9):1074-1076.

Abstract
• Eighty-six thoracic neoplasms, both primary and metastatic, were removed at thoracotomy from 86 patients and were tested for chemosensitivity in the clonogenic assay. Substantial tumor growth was achieved in 79% (67/86). Fifty-two percent (16/31) of the primary lung tumors and 45% (15/33) of the metastatic tumors were sensitive to at least one tested drug. Clinical correlations between in vitro chemosensitivity and in vivo response were possible in 20 patients. The assay was 83% accurate for predicting in vivo sensitivity and 86% accurate for predicting in vivo resistance. The value of the assay as it pertains to lung cancer has been demonstrated. On the basis of the results, thoracotomy is indicated in selected patients as a diagnostic procedure to obtain tissue for chemosensitivity testing.

(Arch Surg 1983;118:1074-1076)

Author Affiliations
From the Division of Oncology, Department of Surgery, UCLA School of Medicine (Drs Bertelsen, Kern, Kaiser, Mann, Holmes, and Morton), and the Surgical Service, Veterans Administration Medical Center, Sepulveda, Calif (Drs Kern, Holmes, and Morton).

Footnotes
Accepted for publication Feb 21, 1983.

Reprint requests to Division of Surgical Oncology, Factor Building, Ninth Floor, UCLA School of Medicine, Los Angeles, CA 90024 (Dr Bertelsen).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?